FN2 Earnings Intelligence
Kymera Therapeutics, Inc. income statement
Kymera Therapeutics, Inc. (KYMR) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $48 | $68.4 | $110 | $120.3 | $357 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $72.8 | $46.8 | $78.6 | $47.1 | $39.2 |
| % Growth | 114.0% | -35.7% | 67.8% | -40.1% | -16.7% |
| Gross Profit | - | - | - | $0 | $0 |
| % Margin | - | - | - | 0.0% | 0.0% |
| EBITDA | -$98.1 | -$158.3 | -$162 | -$254.3 | -$341.1 |
| % Margin | -134.7% | -338.0% | -206.1% | -540.2% | -869.9% |
| Net Income | -$100.2 | -$154.8 | -$147 | -$223.9 | -$311.4 |
| % Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
| Diluted EPS | - | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| % Growth | - | - | 12.2% | -18.3% | -23.8% |
| Operating Cash Flow | -$128.9 | -$153.1 | -$102.8 | -$194.5 | -$232.9 |
| CapEx | $1.6 | $2.8 | $34.5 | $12.8 | $1.4 |
| Free Cash Flow | -$130.5 | -$155.9 | -$137.3 | -$207.3 | -$234.3 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $72.8 | $46.8 | $78.6 | $47.1 | $39.2 |
| Gross Profit | - | - | - | $0 | $0 |
| EBITDA | -$98.1 | -$158.3 | -$162 | -$254.3 | -$341.1 |
| Net Income | -$100.2 | -$154.8 | -$147 | -$223.9 | -$311.4 |
| Diluted EPS | - | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $48 | $68.4 | $110 | $120.3 | $357 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$128.9 | -$153.1 | -$102.8 | -$194.5 | -$232.9 |
| Capital Expenditure | $1.6 | $2.8 | $34.5 | $12.8 | $1.4 |
| Free Cash Flow | -$130.5 | -$155.9 | -$137.3 | -$207.3 | -$234.3 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 114.0% | -35.7% | 67.8% | -40.1% | -16.7% |
| Gross Margin | - | - | - | 0.0% | 0.0% |
| EBITDA Margin | -134.7% | -338.0% | -206.1% | -540.2% | -869.9% |
| Net Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
| FCF Margin | -179.2% | -333.0% | -174.7% | -440.5% | -597.6% |
| Diluted EPS Growth | - | - | 12.2% | -18.3% | -23.8% |
Get the KYMR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.